No retraction, correction or concern found when last checked on Oct 21, 2026.

Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia

Candice R. Gurbatri, Georgette A. Radford, Laura Vrbanac and 34 more

Nature Communications · 2024 · CC BY

Abstract

Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic E. coli Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178). We detect enrichment of EcN in tumor samples over normal tissue from probiotic-treated patients (primary outcome of the trial). Next, we develop early CRC intervention strategies. To detect lesions, we engineer EcN to produce a small molecule, salicylate. Oral delivery of this strain results in increased levels of salicylate in the urine of adenoma-bearing mice, in comparison to healthy controls. To assess therapeutic potential, we engineer EcN to locally release a cytokine, GM-CSF, and blocking nanobodies against PD-L1 and CTLA-4 at the neoplastic site, and demonstrate that oral delivery of this strain reduces adenoma burden by ~50%. Together, these results support the use of EcN as an orally-deliverable platform to detect disease and treat CRC through the production of screening and therapeutic molecules.

References 68

1.
Mazzolini, R. et al. Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms. Nat. Biotechnol.41, 1089–1098 (2023).
Not in our library10.1038/s41587-022-01584-9
2.
Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes · 2022
No notice
3.
Whitfill T, Oh J. Recoding the metagenome: microbiome engineering in situ. Curr. Opin. Microbiol. 2019;50:28-34.
Not in our library10.1016/j.mib.2019.09.005
4.
Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer. 2010;10:785-794.
Not in our library10.1038/nrc2934
5.
Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. Curr. Opin. Syst. Biol. 2017;5:1-8.
Not in our library10.1016/j.coisb.2017.05.009
6.
Bacteria-cancer interactions: bacteria-based cancer therapy · 2019
No notice
7.
Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. Science. 2022;378:858-864.
Not in our library10.1126/science.add9667
8.
Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation · 2017
No notice
9.
Mao N, Cubillos-Ruiz A, Cameron DE, Collins JJ. Probiotic strains detect and suppress cholera in mice. Sci. Transl. Med. 2018;10:eaao2586.
Not in our library10.1126/scitranslmed.aao2586
10.
Robinson CM, Short NE, Riglar DT. Achieving spatially precise diagnosis and therapy in the mammalian gut using synthetic microbial gene circuits. Front. Bioeng. Biotechnol. 2022;10:959441.
Not in our library10.3389/fbioe.2022.959441
11.
Munck C, Sheth RU, Freedberg DE, Wang HH. Recording mobile DNA in the gut microbiota using an Escherichia coli CRISPR-Cas spacer acquisition platform. Nat. Commun. 2020;11:95.
Not in our library10.1038/s41467-019-14012-5
12.
Schmidt F, et al. Noninvasive assessment of gut function using transcriptional recording sentinel cells. Science. 2022;376:eabm6038.
Not in our library10.1126/science.abm6038
13.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: Cancer J. 2020;70:7-30.
Not in our library10.3322/caac.21590
14.
Lin JS, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. Jama. 2016;315:2576-2594.
Not in our library10.1001/jama.2016.3332
15.
Regula J, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 2006;355:1863-1872.
Not in our library10.1056/nejmoa054967
16.
Kew GS, Koh CJ. Strategies to improve persistent adherence in colorectal cancer screening. Gut Liver. 2020;14:546.
Not in our library10.5009/gnl19306
17.
Nian J, et al. Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: a systematic review and meta-analysis. Clin. Transl. Gastroenterol. 2017;8:e216.
Not in our library10.1038/ctg.2016.66
18.
The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis · 2017
No notice
19.
Burn J, Sheth H. The role of aspirin in preventing colorectal cancer. Br. Med. Bull. 2016;119:17-24.
Not in our library10.1093/bmb/ldw028
20.
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial · 2020
No notice
21.
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer · 2017
No notice
22.
Ahmed M. Colon cancer: a clinician’s perspective in 2019. Gastroenterol. Res. 2020;13:1.
Not in our library10.14740/gr1239
23.
Germani MM, Moretto R. Immune checkpoint inhibitors in mismatch repair proficient/microsatellite stable metastatic colorectal cancer patients: Insights from the AtezoTRIBE and MAYA trials. Cancers. 2021;14:52.
Not in our library10.3390/cancers14010052
24.
André T, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N. Engl. J. Med. 2020;383:2207-2218.
Not in our library10.1056/nejmoa2017699
25.
Chalabi M, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 2020;26:566-576.
Not in our library10.1038/s41591-020-0805-8
26.
Zhang Y, et al. Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl. Environ. Microbiol. 2012;78:7603-7610.
Not in our library10.1128/aem.01390-12
27.
Danino T, et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 2015;7:289ra284-289ra284.
Not in our library10.1126/scitranslmed.aaa3519
28.
Bioengineered Escherichia coli Nissle 1917 for tumour‐targeting therapy · 2020
Not checked
29.
Zeineldin M, Neufeld KL. More than two decades of APC modeling in rodents. Biochim. Biophys. Acta (BBA) Rev. Cancer. 2013;1836:80-89.
Not in our library10.1016/j.bbcan.2013.01.001
30.
Kwong, L. N. & Dove, W. F. APC and its modifiers in colon cancer. Adv. Exp. Med. Biol.656, 85–106 (2009).
Not in our library10.1007/978-1-4419-1145-2_8
31.
Danino T, Lo J, Prindle A, Hasty J, Bhatia SN. In vivo gene expression dynamics of tumor-targeted bacteria. ACS Synth. Biol. 2012;1:465-470.
Not in our library10.1021/sb3000639
32.
Din MO, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature. 2016;536:81-85.
Not in our library10.1038/nature18930
33.
Gurbatri CR, et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. 2020;12:eaax0876.
Not in our library10.1126/scitranslmed.aax0876
34.
Pleguezuelos-Manzano C, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature. 2020;580:269-273.
Not in our library10.1038/s41586-020-2080-8
35.
Oligosaccharides increase the genotoxic effect of colibactin produced by pks+ Escherichia coli strains · 2021
Not checked
36.
Wallenstein A, et al. ClbR is the key transcriptional activator of colibactin gene expression in Escherichia coli. MSphere. 2020;5:e00591-00520.
Not in our library10.1128/msphere.00591-20
37.
Kalantari A, et al. Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster. PLoS One. 2023;18:e0280499.
Not in our library10.1371/journal.pone.0280499
38.
Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut · 2019
No notice
39.
Ho CL, et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat. Biomed. Eng. 2018;2:27-37.
Not in our library10.1038/s41551-017-0181-y
40.
Grabig A, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect. Immun. 2006;74:4075-4082.
Not in our library10.1128/iai.01449-05
41.
Lannagan TR, et al. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut. 2019;68:684-692.
Not in our library10.1136/gutjnl-2017-315920
42.
Ahn J, et al. Human gut microbiome and risk for colorectal cancer. J. Natl Cancer Inst. 2013;105:1907-1911.
Not in our library10.1093/jnci/djt300
43.
Kaltenbach T, et al. Endoscopic removal of colorectal lesions—recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020;158:1095-1129.
Not in our library10.1053/j.gastro.2019.12.018
44.
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer · 2022
No notice
45.
Poore GD, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567-574.
Not in our library10.1038/s41586-020-2095-1
46.
Dejea CM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl Acad. Sci. USA. 2014;111:18321-18326.
Not in our library10.1073/pnas.1406199111
47.
Blum-Oehler G, et al. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res. Microbiol. 2003;154:59-66.
Not in our library10.1016/s0923-2508(02)00007-4
48.
Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT · 2013
No notice
49.
Lawrence J, et al. Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. J. Clin. Pathol. 2003;56:651-653.
Not in our library10.1136/jcp.56.9.651
50.
Chien T, Jones DR, Danino T. Engineered bacterial production of volatile methyl salicylate. ACS Synth. Biol. 2020;10:204-208.
Not in our library10.1021/acssynbio.0c00497
51.
Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants · 2018
Not checked
52.
Chowdhury S, et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med. 2019;25:1057-1063.
Not in our library10.1038/s41591-019-0498-z
53.
Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients · 2021
Not checked
54.
Ganesh K, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019;16:361-375.
Not in our library10.1038/s41575-019-0126-x
55.
Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 2019;25:3074-3083.
Not in our library10.1158/1078-0432.ccr-18-1942
56.
Parker TW, Neufeld KL. APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes. Sci. Rep. 2020;10:1-14.
Not in our library10.1038/s41598-020-59899-z
57.
Joeres-Nguyen-Xuan TH, Boehm SK, Joeres L, Schulze J, Kruis W. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflamm. Bowel Dis. 2010;16:256-262.
Not in our library10.1002/ibd.21042
58.
Zou Z-P, Du Y, Fang T-T, Zhou Y, Ye B-C. Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice. Cell Host Microbe. 2023;31:199-212. e195.
Not in our library10.1016/j.chom.2022.12.004
59.
Yu YA, Zhang Q, Szalay AA. Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. Biotechnol. Bioeng. 2008;100:567-578.
Not in our library10.1002/bit.21785
60.
Zmora N, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174:1388-1405. e1321.
Not in our library10.1016/j.cell.2018.08.041
61.
Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect. 2015;17:173-183.
Not in our library10.1016/j.micinf.2015.01.004
62.
Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat. Rev. Microbiol. 2010;8:26-38.
Not in our library10.1038/nrmicro2265
63.
Abed J, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20:215-225.
Not in our library10.1016/j.chom.2016.07.006
64.
Murphy KC, Campellone KG. Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Mol. Biol. 2003;4:1-12.
Not in our library10.1186/1471-2199-4-11
65.
Becker C, Fantini M, Neurath M. High resolution colonoscopy in live mice. Nat. Protoc. 2006;1:2900-2904.
Not in our library10.1038/nprot.2006.446
66.
A new genomic blueprint of the human gut microbiota · 2019
No notice
67.
Yuqin Dai, J. J. H. Discovery Metabolomics LC/MS Methods Optimized for Polar Metabolites (Agilent Technologies, Inc., 2019).
Not in our library
68.
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem.78, 779–787 (2006).
Not in our library10.1021/ac051437y

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.